Sinovac Life Sciences Co., Ltd.

Related records

Trials (29)

• A Phase Ⅲ Clinical Study of SNA02-48 Injection
• Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine
• Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals
• Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days)
• Clinical Trial of PCV24 in Adults
• Clinical Trial of PCV24 in Adults Aged ≥18 Years
• Clinical Trial of PCV24 in Children Aged 2-17 Years
• Clinical Trial of PCV24 in Infants Aged 2-23 Months
• Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years
• Efficacy and Safety of Anti-COVID-19 Antibody SA58 Nasal Spray to Prevent Infection in High-risk Populations
• Efficacy and Safety of SA58 Nasal Spray in Close Contact With COVID-19 People
• Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine
• Immunogenicity and Safety of a Third Dose of COVID-19 Vaccine(Vero Cell), Inactivated in the Elderly
• Immunogenicity and Safety Study of One Booster Dose of Trivalent COVID-19 Vaccine (Vero Cell), Inactivated
• Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in Chile
• Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 Vaccine
• Phase Ia Clinical Trial of Group ACYW135X Meningococcal Conjugate Vaccine
• PhaseⅡClinical Trial of Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)
• SA55 Injection Phase II Study in the Treatment of Mild/Moderate COVID-19 Patients
• SA55 Injection: a Potential Therapy for the Prevention and Treatment of COVID-19